PBYI - NASDAQ
Puma Biotechnology, Inc.
$6.83
-2.2%Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
At a Glance
Live SnapshotPuma Biotechnology, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Healthy operating margins demonstrate effective cost control and strong business fundamentals.
Net Profit Margin
Strong net margins indicate efficient operations and favorable tax/interest management.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Puma Biotechnology, Inc. Income Statement
PBYI • NASDAQ
| Puma Biotechnology, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||||||||||
228.4M | 230.5M | 235.6M | 228M | 253.2M | 225.1M | 272.3M | 251M | 27.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -281.1K | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | |||||||||||||||||||
(58.2M) | (64.4M) | (62.7M) | (55.1M) | (63.7M) | (39.4M) | (36.8M) | (34.6M) | (5.6M) | (1.1M) | (776K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
170.2M | 166.1M | 173M | 172.9M | 189.5M | 185.7M | 235.5M | 216.4M | 22.1M | -1.1M | -776K | 0.0 | 0.0 | 0.0 | -281.1K | 0.0 | 0.0 | 0.0 | 0.0 | |
OPERATING INCOME | |||||||||||||||||||
(132.9M) | (135.1M) | (140.3M) | (149.2M) | (188.2M) | (216.1M) | (274.6M) | (311.1M) | (314.5M) | (276.6M) | (240.3M) | (142.3M) | (54.8M) | (74.4M) | (10.2M) | (16K) | (16.8K) | (14.1K) | -15.1M | |
(70.8M) | (80.2M) | (89.3M) | (90M) | (116.3M) | (118.5M) | (141.7M) | (146.2M) | (106.7M) | (53.8M) | (31.8M) | (19.4M) | (9.8M) | (24.8M) | (9.3M) | (16K) | (16.8K) | (14.1K) | (0.0) | |
(62.1M) | (54.9M) | (50.4M) | (52.2M) | (71.9M) | (97.7M) | (132.9M) | (164.9M) | (207.8M) | (222.8M) | (208.5M) | (122.9M) | (45M) | (49.6M) | (826.4K) | (0.0) | (0.0) | (0.0) | (0.0) | |
37.3M | 31M | 32.6M | 23.7M | 1.3M | -30.4M | -39.1M | -94.7M | -292.4M | -276.6M | -240.3M | -142.3M | -54.8M | -74.4M | -10.2M | -16K | -16.8K | -14.1K | -15.1M | |
PRE-TAX INCOME | |||||||||||||||||||
(6.6M) | (12.5M) | (13.3M) | (11.6M) | (12.8M) | (14M) | (15M) | (11M) | (720K) | (958K) | (971K) | (324K) | (172K) | (98K) | (3.8K) | (0.0) | (0.0) | (0.0) | (0.0) | |
-2.5M | -7.7M | -10.7M | -10.8M | -12.6M | -13.6M | -12.2M | -9.2M | 536K | 42K | 29K | -24K | 0.0 | 2K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | (625K) | (7M) | (0.0) | (0.0) | (0.0) | (0.0) | -100K | -400K | (25K) | -14K | (2K) | (293K) | (10.7K) | (0.0) | (0.0) | (0.0) | -15.1M | |
-1.5M | -6.9M | -10M | -23.3M | -30.1M | -29.4M | 53K | -18.9M | 435K | 585K | 996K | 310K | 174K | 98K | -76.2K | 0.0 | 0.0 | 0.0 | 0.0 | |
35.8M | 24.1M | 22.7M | 457K | -28.8M | -59.8M | -75.6M | -113.6M | -292M | -276M | -239.3M | -142M | -54.7M | -74.3M | -10.2M | -16K | -16.8K | -14.1K | -15.1M | |
NET INCOME | |||||||||||||||||||
(4.7M) | -6.2M | (1.1M) | (455K) | (324K) | (207K) | (7.1M) | -7.9M | -2.2M | -2.1M | -1.8M | -941K | -172K | -267K | (76.2K) | (0.0) | (0.0) | (0.0) | (0.0) | |
31.1M | 30.3M | 21.6M | 2K | -29.1M | -60M | -75.6M | -113.6M | -292M | -276M | -239.3M | -142M | -54.7M | -74.3M | -10.2M | -16K | -16.8K | -14.1K | -15.1M |
SEC Filings
PBYI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 11, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 07, 2025 | August 07, 2025 | 2025 | |
10-Q/A 10-Q/A 2025 Q1 (Amended) Q1 | August 07, 2025 | March 31, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 07, 2025 | June 30, 2025 | 2025 |
Related Guides
Continue your PBYI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.